SA522440646B1 - أجسام مضادة ترتبط بـ siglec15 واستخداماتها - Google Patents
أجسام مضادة ترتبط بـ siglec15 واستخداماتهاInfo
- Publication number
- SA522440646B1 SA522440646B1 SA522440646A SA522440646A SA522440646B1 SA 522440646 B1 SA522440646 B1 SA 522440646B1 SA 522440646 A SA522440646 A SA 522440646A SA 522440646 A SA522440646 A SA 522440646A SA 522440646 B1 SA522440646 B1 SA 522440646B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- antigen
- binding portion
- antibody
- siglec15
- provides
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Physical Education & Sports Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063000566P | 2020-03-27 | 2020-03-27 | |
| PCT/CN2021/083194 WO2021190622A1 (en) | 2020-03-27 | 2021-03-26 | Antibodies binding siglec15 and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SA522440646B1 true SA522440646B1 (ar) | 2024-08-29 |
Family
ID=77891322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA522440646A SA522440646B1 (ar) | 2020-03-27 | 2022-09-25 | أجسام مضادة ترتبط بـ siglec15 واستخداماتها |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11739147B2 (https=) |
| EP (1) | EP4126938A4 (https=) |
| JP (2) | JP7364315B2 (https=) |
| KR (1) | KR102651263B1 (https=) |
| CN (1) | CN115348970B (https=) |
| AU (2) | AU2021240769B2 (https=) |
| BR (1) | BR112022019129A2 (https=) |
| IL (1) | IL296736B2 (https=) |
| MX (1) | MX2022011951A (https=) |
| PH (1) | PH12022552520A1 (https=) |
| SA (1) | SA522440646B1 (https=) |
| WO (1) | WO2021190622A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021240769B2 (en) * | 2020-03-27 | 2023-04-06 | Biosion Inc. | Antibodies binding Siglec15 and uses thereof |
| US20260070974A1 (en) * | 2021-11-25 | 2026-03-12 | Nona Biosciences (Suzhou) Co., Ltd. | Anti-siglec-15 antibody and use thereof |
| CN114134183B (zh) * | 2021-12-24 | 2022-12-06 | 广东南模生物科技有限公司 | 一种siglec15基因人源化动物模型的构建方法及应用 |
| CN114807052A (zh) * | 2022-06-07 | 2022-07-29 | 江苏亲科生物研究中心有限公司 | Siglec15单克隆抗体及其制备方法和用途 |
| CA3259231A1 (en) * | 2022-06-13 | 2023-12-21 | Shanghai Institute Of Biological Products Co., Ltd. | ANTI-SIGLEC15 ANTIBODIES AND THEIR USES |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| WO2025247334A1 (en) * | 2024-05-30 | 2025-12-04 | Biosion Inc. | Recombinant fusion protein targeting siglec15 and gm-csfr |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4604184B2 (ja) * | 2005-07-12 | 2010-12-22 | 独立行政法人産業技術総合研究所 | 新規糖鎖認識蛋白質及びその遺伝子 |
| US8168181B2 (en) * | 2006-02-13 | 2012-05-01 | Alethia Biotherapeutics, Inc. | Methods of impairing osteoclast differentiation using antibodies that bind siglec-15 |
| JP2013543382A (ja) * | 2010-10-05 | 2013-12-05 | 第一三共株式会社 | 破骨細胞関連蛋白質Ｓｉｇｌｅｃ−１５を標的とした抗体 |
| ES2908046T3 (es) | 2011-09-09 | 2022-04-27 | Medimmune Ltd | Anticuerpos anti-siglec-15 y usos de los mismos. |
| EP2832855A4 (en) * | 2012-03-30 | 2016-02-24 | Daiichi Sankyo Co Ltd | NOVEL ANTI-SIGLEC-15 ANTIBODY |
| US9493562B2 (en) * | 2012-07-19 | 2016-11-15 | Alethia Biotherapeutics Inc. | Anti-Siglec-15 antibodies |
| WO2015192214A1 (en) * | 2014-06-18 | 2015-12-23 | Alethia Biotherapeutics Inc. | Anti-siglec-15 antibodies for use in treatment of osteogenesis imperfecta |
| HK1259294A1 (zh) | 2015-11-10 | 2019-11-29 | 耶鲁大学 | 用於治疗自身免疫疾病和癌症的组合物及方法 |
| AU2017330346C1 (en) * | 2016-09-21 | 2025-03-06 | Nextcure, Inc. | Antibodies for Siglec-15 and methods of use thereof |
| CN108250296B (zh) * | 2018-01-17 | 2020-07-07 | 长春金赛药业有限责任公司 | 全人源抗人pd-l1单克隆抗体及其应用 |
| JP7156653B2 (ja) * | 2018-08-30 | 2022-10-19 | イノベイティブ セルラー セラピューティクス ホールディングス，エルティディ | 固形腫瘍を治療するためのキメラ抗原受容体細胞 |
| AU2021240769B2 (en) * | 2020-03-27 | 2023-04-06 | Biosion Inc. | Antibodies binding Siglec15 and uses thereof |
-
2021
- 2021-03-26 AU AU2021240769A patent/AU2021240769B2/en active Active
- 2021-03-26 EP EP21774588.4A patent/EP4126938A4/en active Pending
- 2021-03-26 JP JP2022547787A patent/JP7364315B2/ja active Active
- 2021-03-26 MX MX2022011951A patent/MX2022011951A/es unknown
- 2021-03-26 CN CN202180024369.4A patent/CN115348970B/zh active Active
- 2021-03-26 KR KR1020227030409A patent/KR102651263B1/ko active Active
- 2021-03-26 BR BR112022019129A patent/BR112022019129A2/pt unknown
- 2021-03-26 WO PCT/CN2021/083194 patent/WO2021190622A1/en not_active Ceased
- 2021-03-26 IL IL296736A patent/IL296736B2/en unknown
- 2021-03-26 PH PH1/2022/552520A patent/PH12022552520A1/en unknown
-
2022
- 2022-09-25 SA SA522440646A patent/SA522440646B1/ar unknown
- 2022-09-27 US US17/935,815 patent/US11739147B2/en active Active
-
2023
- 2023-05-31 AU AU2023203397A patent/AU2023203397A1/en active Pending
- 2023-06-23 US US18/340,367 patent/US20240002508A1/en active Pending
- 2023-10-03 JP JP2023172391A patent/JP7827951B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR102651263B1 (ko) | 2024-03-25 |
| IL296736B1 (en) | 2024-12-01 |
| CA3173201A1 (en) | 2021-09-30 |
| NZ792658A (en) | 2024-07-05 |
| US11739147B2 (en) | 2023-08-29 |
| IL296736A (en) | 2022-11-01 |
| AU2021240769B2 (en) | 2023-04-06 |
| BR112022019129A2 (pt) | 2022-12-06 |
| US20240002508A1 (en) | 2024-01-04 |
| CN115348970B (zh) | 2023-11-14 |
| WO2021190622A1 (en) | 2021-09-30 |
| AU2023203397A1 (en) | 2023-06-29 |
| US20230106715A1 (en) | 2023-04-06 |
| JP7364315B2 (ja) | 2023-10-18 |
| EP4126938A1 (en) | 2023-02-08 |
| MX2022011951A (es) | 2023-03-06 |
| CN115348970A (zh) | 2022-11-15 |
| EP4126938A4 (en) | 2024-04-10 |
| PH12022552520A1 (en) | 2023-01-04 |
| JP2023518153A (ja) | 2023-04-28 |
| IL296736B2 (en) | 2025-04-01 |
| KR20220158696A (ko) | 2022-12-01 |
| AU2021240769A1 (en) | 2022-10-20 |
| JP7827951B2 (ja) | 2026-03-11 |
| JP2024016024A (ja) | 2024-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA522440646B1 (ar) | أجسام مضادة ترتبط بـ siglec15 واستخداماتها | |
| MX2022010665A (es) | Anticuerpos que se unen al receptor de interleucina 4 (il4r) y usos de los mismos. | |
| JOP20200078B1 (ar) | أجسام مضادة خاصة بـ cd47 وpd-l1 | |
| MY205758A (en) | Anti-nkg2a antibodies and uses thereof | |
| EA202090247A1 (ru) | Антитела против cd166 и их применения | |
| ZA202308896B (en) | Antibodies binding trop2 and uses thereof | |
| MX2024006968A (es) | Anticuerpos cdh17 y metodos de tratamiento del cancer. | |
| BRPI0607757A2 (pt) | anticorpo, composição, imunoconjugado, molécula bi-especìfica, molécula de ácido nucleico isolado, vetor de expressão, célula hospedeira, hibridoma, método para preparar um anticorpo anti-psma, e, usos de um anticorpo, ou porção de ligação a antìgeno do mesmo | |
| EA201990781A9 (ru) | Анти-steap2 антитела, конъюгаты антитело-лекарственное средство и биспецифические антигенсвязывающие молекулы, которые связывают steap2 и cd3, и их применение | |
| EA201791666A1 (ru) | Антитела к cd3, антитела к cd123 и биспецифические антитела, которые специфически связываются с cd3 и/или cd123 | |
| HRP20240415T1 (hr) | Kimerni antigenski receptori antigena kapa mijeloma i njihova upotreba | |
| UA99701C2 (ru) | Человеческое моноклональное антитело, которое специфически связывается с лигандом-1 запрограммированной гибели клеток (pd-l1) | |
| ZA202408388B (en) | Antibodies targeting sirp-alpha and uses thereof | |
| EA201590208A1 (ru) | Усиление активности т-клеток car путем совместного введения биспецифического антитела | |
| FI3683235T3 (fi) | Anti-IL-33-vasta-aineita ja niiden käyttöjä | |
| AR047372A1 (es) | Anticuerpos contra madcam | |
| EA201101242A1 (ru) | Полностью человеческие антитела, специфические для cadm1 | |
| PH12020551012A1 (en) | Monoclonal antibodies and methods for using same | |
| EA202091747A1 (ru) | Составы антитела b7-h4 | |
| WO2019060750A3 (en) | A33 antibody compositions and methods of using the same in radioimmunotherapy | |
| JOP20210286A1 (ar) | جسم مضاد أحادي النسيلة يرتبط نوعياً مع gitr | |
| MX2023009022A (es) | Anticuerpos multiespecificos con especificidad para ror1 y cd3. | |
| AU2019433019A8 (en) | Antibodies binding CD40 and uses thereof | |
| EA201992206A1 (ru) | Моноклональное антитело к pd-l1 | |
| EA202290208A1 (ru) | МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА, КОТОРЫЕ СВЯЗЫВАЮТ EGFRvIII, И ИХ ПРИМЕНЕНИЕ |